A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of BGM1812 in Healthy and Non-diabetic Overweight or Obese Chinese Participants
Latest Information Update: 25 Dec 2025
At a glance
- Drugs BGM 1812 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 25 Dec 2025 New trial record